The guarantee is conditional and requires demonstrated adherence to the program
As TCTMD reported at the time, excitement ran high at the American Diabetes Association 2022 Scientific Sessions when the SURMOUNT trial of once-weekly tirzepatide in obese patients without diabetes demonstrated a magnitude of weight loss similar to what is typically seen with gastric bypassabout 20% of bodyweight versus the typical 15% seen with semaglutide
Ogata, S., Misumi, Y., Tsuji, E., Takami, N., Oda, K., and Ikehara, Y
10.1186/s12933-016-0468-4 9
Are you curious about at-home prescription weight loss treatment
Supplements vs